BBH - VanEck Vectors Biotech ETF
| Previous Close | 129.33 |
| Open | 129.05 |
| Bid | 121.64 x 1400 |
| Ask | 131.99 x 1300 |
| Day's Range | 128.67 - 129.63 |
| 52 Week Range | 111.36 - 136.83 |
| Volume | 7,047 |
| Avg. Volume | 18,542 |
| Net Assets | 462.64M |
| NAV | 128.64 |
| PE Ratio (TTM) | N/A |
| Yield | 0.53% |
| YTD Return | 3.23% |
| Beta (3y) | 1.44 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2011-12-20 |
- Market Realist•yesterday
Considering Allergan’s Q2 2018 Revenue Trend
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.
- Market Realist•10 days ago
What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.
- Market Realist•15 days ago
Bluebird Bio Misses Analysts’ Estimates in Q2 2018
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.
- Investopedia•16 days ago
Adding Biotech ETFs to Your Portfolio
As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.
- Market Realist•18 days ago
What Analysts Recommend for Bluebird Bio Stock
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter. Of the 21 analysts tracking Bluebird Bio, five recommend “strong buy,” nine recommend “buy,” six recommend “hold,” and one recommends “sell.”
- Market Realist•18 days ago
Shire’s Q2 2018 Earnings Beat Analyst Estimates
Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018, compared to estimates for EPS of $3.67 on revenues of $3.8 billion.
- ETF Trends•last month
Biotech ETFs Climb on Biogen’s Promising Clinical Trial
Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq ...
- Zacks•2 months ago
Top-Ranked Sector ETFs to Buy for Q3
These sector ETFs have a Zacks Rank #1 or 2 and are likely to outperform ahead.
- Market Realist•3 months ago
What Drove Ionis’s Revenue in Q1
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
- Market Realist•3 months ago
BlueBird Bio Stock Jumps over 6% on May 17
BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.
- Market Realist•3 months ago
Allergan Reports Growth in 1Q18 Revenues
Headquartered in Ireland, Allergan (AGN) develops, manufactures, and commercializes pharmaceutical products and devices, as well as biologic products. On April 30, Allergan reported 2.8% revenue growth to ~$3.7 billion in 1Q18, compared to revenues of ~$3.6 billion in 1Q17. The chart below shows Allergan’s revenues since 1Q17.
- Market Realist•4 months ago
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Pharmaceutical giant Allergan (AGN) is set to release its 1Q18 earnings on April 30. Wall Street analysts estimate that the company could report earnings per share (or EPS) of $3.36 on revenues of $3.6 billion for 1Q18.
- Market Realist•5 months ago
What’s Ionis Pharmaceuticals’ Valuation in March 2018?
How Ionis Pharmaceuticals Is Positioned in 2018A look at Ionis Pharmaceuticals
- Market Realist•5 months ago
A Look at Incyte’s Valuation in March 2018
Who’s Watching Incyte Corporation in March 2018?Incyte Corporation
- Motley Fool•5 months ago
The 4 Top Biotech ETFs
Investing in biotechnology has been very lucrative lately, and these funds can help you tap into the industry's success.
- Market Realist•5 months ago
Gilead Sciences: Analysts’ Estimates after 4Q17
What Could Drive Gilead Sciences' Valuation in March?
- InvestorPlace•7 months ago
4 ETFs Set to Surge Amid Q4 Earnings
The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter. The S&P 500 index is anticipated to see earnings growth of 9.2% and revenue growth of 7%. The market is also at record levels, scaling series of highs at the start of the year.Source: Shutterstock
- Market Realist•7 months ago
A Look at Ionis’s 3Q17 Revenue Stream
What's the Word on Ionis Pharmaceuticals This January?
- Market Realist•7 months ago
How Was Incyte’s Revenue Stream in 3Q17?
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
- Business Wire•8 months ago
VanEck Announces Yearend Distributions for VanEck Vectors Equity ETFs
VanEck announced today the following 2017 annual distributions per share for its VanEck Vectors® equity exchange-traded funds.
- Business Wire•9 months ago
VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs
VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.
- Market Realist•11 months ago
Benefitting from IBB’s Lower Expense Ratio
The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.
- Market Realist•11 months ago
How Gilead’s HIV and HBV Portfolios Performed in 2Q17
Gilead Sciences' (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.
- CNBC Videos•10 months ago
Investors getting back into M&A : York Capital co-CEO
Daniel Schwartz, York Capital Management co-CEO, weighs in on the strength of the M&A market and where he sees the biggest opportunities, including biotechnology and the telecom industry.
